title: [Assessment of risk of cerebral infarction and benefit of anticoagulant therapy in a patient with atrial fibrillation].
abstract: The risk of cerebral infarction in patients with atrial fibrillation varies from 0.5% to more than 10% per year. Anticoagulant therapy is recommended today more than before, but to a low-risk patient anticoagulation may cause harm that is larger than the expected benefit. Assessment of the risk of cerebral infarction is therefore essential. Use of the CHA2DS2-VASc risk index enables reliable identification of low-risk patients who do not benefit from anticoagulation. Individual treatment decisions may even be necessary.
authors.forename: Matti
authors.initials: M
authors.lastname: Halinen
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D002544:Cerebral Infarction / Q000139:chemically induced*; D003657:Decision Making; D006801:Humans; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000925:Anticoagulants
vernacular_title: Eteisvärinäpotilaan aivoinfarktin vaaran ja antikoagulaatiohoidon hyödyn arviointi.